The goal of the price of Janux Therapeutics has decreased to $ 41 with $ 62 in Scotiabank

Scotiabank has dropped the company goal on Janux therapyutics (Yang) up to $ 41 from $ 62 and maintains a sector of grades on stakeholders. Although the results of the dose escalation for the current Phase 1 trial 1 in phase 1 Janx007 look promising, the company does not believe that all the benchmarks are required to establish a competitive edges and potential acquisition of pharmacy, the analyst tells investors. The company reduces its own goal reflect the muted view of the potential of Janx007.

Published first on Thefly -Real -time short source, on the market that moves in breaking the financial news. Try now >>

Look at the hot stock of insiders on the Tipranks >>

Read more about Janx: